To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Methods: All antiretroviral therapy (ART)-naïve and ART-experienced HIV-infected individuals from the Swiss HIV Cohort Study who initiated raltegravir or dolutegravir between 2006 and 2015 were investigated concerning treatment modification within the first ...

The Bill and Melinda Gates Foundation is to invest up to $40 million in privately held British biotech company Immunocore to support its development of immunotherapies for infectious diseases. Oxford-based Immunocore has so far concentrated on developing its T-cell receptor medicines to fight cancer, where it ...

The aim of the study was to assess, among people living with HIV, knowledge of their latest HIV viral load (VL) and CD4 count. Methods Agreement between self-report and clinic record was assessed among 2771 HIV-diagnosed individuals on antiretroviral treatment (ART) in the UK Antiretrovirals, Sexual Transmission ...

HIV-positive U.S. residents in the large NA-ACCORD cohort had an atherosclerotic myocardial infarction (MI) rate 20% higher than people in a U.S. general-population cohort, newly published data reveal. This 29,169-person analysis also linked MI risk to lower CD4 count, higher viral load and a host ...

AbbVie’s new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. Glecaprevir/pibrentasvir (Maviret) is expected to be approved ...

HVTN 705 vaccine study passes its “go” criteria: due to start this autumn A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, ...

A new joint platform for parallel consultation will provide advice to medicine developers and facilitate access to medicines for patients The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) are stepping up their efforts to provide developers of medicines with simultaneous, coordinated advice ...

Indian scientists from the University of Delhi have identified molecules that could effectively inhibit TB virus and have published all the results of the study in Scientific Reports journal. The molecules are targeting a gene, important for  the bacterium’s survival. Possibly they may find a new ...

Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. People who inject drugs (PWID) are historically viewed as having “difficult to treat” hepatitis C disease, ...

Introduction Pursuant to a license negotiated by the Medicines Patent Pool (MPP) with ViiV Healthcare (ViiV), an important new antiretroviral medicine, dolutegravir (DTG), will soon be available via generic competition in all low- and lower-middle-income countries, and a significant number of upper-middle-income countries as well. DTG ...

Georgia is currently facing a problem of a high incidence of tuberculosis (TB) and relatively low treatment success rates. Many patients are not followed up properly which contributes to high levels of multidrug-resistant TB: 12 % of new patients are resistant to first line drugs. ...

An Activist's Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols. The three tools contained in the toolkit will help Community Advisory Boards (CABs) think through different aspects of trial design and implementation, organize feedback for the research ...

Several anecdotal reports of mouth ulcers have recently been reported in people switching to generic abacavir in the UK. This should highlight awareness of the potential of likely-rare new side effects, even when both formulations have been approved as bioequivalent. These are likely to be very uncommon reactions, ...

Some of the world’s largest funders of medical research and international non-governmental organizations today agreed on new standards that will require all clinical trials they fund or support to be registered and the results disclosed publicly. In a joint statement, the Indian Council of Medical Research, ...

The European Medicines Agency’s (EMA) 2016 annual report published today focuses on the Agency’s key achievements in the areas of medicine evaluation, support to research and development of new and innovative treatments and the safety monitoring of medicines in real life. In 2016, the Agency recommended ...

Research at the University of Illinois at Urbana-Champaign has provided the first evidence that viruses and hosts share highly similar regulatory sequences in their promoters—the initiation sequences of human genes that code for functional proteins. “To date viral-host networks include protein and mRNA interactions between viruses ...

Aidspan, an independent watchdog of the Global Fund to Fight AIDS, Tuberculosis and Malaria, published Issue 309 of the “Global Fund Observer.” The newsletter features articles on various topics, including an article on the release of Aidspan’s Asia Pacific report, which provides an overview of ...

A big data study of hepatitis C and more than 500 patients with the virus has opened the way for a better understanding of how the virus interacts with its human hosts. Researchers at the University of Oxford have for the first time developed a method ...